Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide.

Liu S, Desharnais J, Sahasrabudhe PV, Jin P, Li W, Oates BD, Shanker S, Banker ME, Chrunyk BA, Song X, Feng X, Griffor M, Jimenez J, Chen G, Tumelty D, Bhat A, Bradshaw CW, Woodnutt G, Lappe RW, Thorarensen A, Qiu X, Withka JM, Wood LD.

Sci Rep. 2016 May 17;6:26071. doi: 10.1038/srep26071.

2.

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N.

J Pharmacol Exp Ther. 2013 Aug;346(2):270-80. doi: 10.1124/jpet.113.204420. Epub 2013 May 29.

PMID:
23720456
3.

Development of novel linkers to conjugate pharmacophores to a carrier antibody.

Palanki MS, Bhat A, Lappe RW, Liu B, Oates B, Rizzo J, Stankovic N, Bradshaw C.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4249-53. doi: 10.1016/j.bmcl.2012.05.040. Epub 2012 May 17.

PMID:
22664129
4.

Antitumor efficacy of a thrombospondin 1 mimetic CovX-body.

Li L, Leedom TA, Do J, Huang H, Lai J, Johnson K, Osothprarop TF, Rizzo JD, Doppalapudi VR, Bradshaw CW, Lappe RW, Woodnutt G, Levin NJ, Pirie-Shepherd SR.

Transl Oncol. 2011 Aug;4(4):249-57. Epub 2011 Aug 1.

5.

Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery.

Bower KE, Lam SN, Oates BD, Del Rosario JR, Corner E, Osothprarop TF, Kinhikar AG, Hoye JA, Preston RR, Murphy RE, Campbell LA, Huang H, Jimenez J, Cao X, Chen G, Ainekulu ZW, Datt AB, Levin NJ, Doppalapudi VR, Pirie-Shepherd SR, Bradshaw C, Woodnutt G, Lappe RW.

J Med Chem. 2011 Mar 10;54(5):1256-65. doi: 10.1021/jm101226k. Epub 2011 Jan 31.

PMID:
21280651
6.

Chemical generation of bispecific antibodies.

Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, Parish M, Murphy RE, Del Rosario J, Oates BD, Lai JY, Matin MJ, Ainekulu Z, Bhat A, Bradshaw CW, Woodnutt G, Lerner RA, Lappe RW.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13.

7.

Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization.

Riley RD, Sato H, Zhao ZQ, Thourani VH, Jordan JE, Fernandez AX, Ma XL, Hite DR, Rigel DF, Pellas TC, Peppard J, Bill KA, Lappe RW, Vinten-Johansen J.

J Thorac Cardiovasc Surg. 2000 Aug;120(2):350-8.

8.

Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.

Chatelain RE, Ghai RD, Trapani AJ, Odorico LM, Dardik BN, De Lombaert S, Lappe RW, Fink CA.

J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.

PMID:
9495857
9.

Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage.

Kwan AL, Bavbek M, Jeng AY, Maniara W, Toyoda T, Lappe RW, Kassell NF, Lee KS.

J Neurosurg. 1997 Aug;87(2):281-6.

PMID:
9254094
10.

Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage.

Caner HH, Kwan AL, Arthur A, Jeng AY, Lappe RW, Kassell NF, Lee KS.

J Neurosurg. 1996 Nov;85(5):917-22.

PMID:
8893732
11.

In vitro and in vivo evaluation of an endothelin inhibitor reveals novel K+ channel opening activity.

Webb RL, Hu S, Sills MA, Bazil MK, Cioffi CL, Shetty SS, Lappe RW, Rigel DF.

Biochem Biophys Res Commun. 1996 Oct 3;227(1):176-81.

PMID:
8858121
12.

The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11.

Trapani AJ, De Lombaert S, Erion MD, Ghai RD, Peppard JV, Lappe RW, Worcel M.

J Hypertens Suppl. 1993 Dec;11(5):S220-1. No abstract available.

PMID:
8158354
13.

Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.

Trapani AJ, Balwierczak JL, Lappe RW, Stanton JL, Graybill SC, Hopkins MF, Savage P, Sperbeck DM, Jeng AY.

Biochem Mol Biol Int. 1993 Dec;31(5):861-7.

PMID:
8136704
14.
15.

Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle.

Shetty SS, Okada T, Webb RL, DelGrande D, Lappe RW.

Biochem Biophys Res Commun. 1993 Mar 15;191(2):459-64.

PMID:
8461004
16.
17.

Coupling of endothelin receptors to ion channels in rat glomerular mesangial cells.

Hu S, Kim HS, Lappe RW, Webb RL.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S149-53.

PMID:
7509928
18.

Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats.

Bazil MK, Lappe RW, Webb RL.

J Cardiovasc Pharmacol. 1992 Dec;20(6):940-8.

PMID:
1282597
19.

In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.

Merkel LA, Rivera LM, Perrone MH, Lappe RW.

Eur J Pharmacol. 1992 May 27;216(1):29-35.

PMID:
1326438
20.

Selective adenosine-2 agonist produces both direct and reflex tachycardia in normotensive rats.

Lappe RW, Sheldon JH, Cox BF.

J Cardiovasc Pharmacol. 1992 Mar;19(3):460-3.

PMID:
1378130
21.

Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels.

Merkel LA, Lappe RW, Rivera LM, Cox BF, Perrone MH.

J Pharmacol Exp Ther. 1992 Feb;260(2):437-43.

PMID:
1310735
22.

Infusion of recombinant human prorenin into rhesus monkeys. Effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone.

Lenz T, Sealey JE, Lappe RW, Carilli C, Oshiro GT, Baxter JD, Laragh JH.

Am J Hypertens. 1990 Apr;3(4):257-61.

PMID:
2189442
23.

Effects of atrial natriuretic factor in conscious rhesus monkeys with acute volume expansion.

Lee KC, Greenwood JM, Wendt RL, Lappe RW.

Am J Hypertens. 1990 Apr;3(4):262-7.

PMID:
2140688
24.
25.

Cardiovascular effects of central calcitonin gene-related peptide in conscious rats.

Lappe RW, Todt JA, Wendt RL.

Am J Hypertens. 1988 Jan;1(1):47-9.

PMID:
3259432
27.

Hemodynamic effects of calcitonin gene-related peptide in conscious rats.

Lappe RW, Slivjak MJ, Todt JA, Wendt RL.

Regul Pept. 1987 Dec;19(5-6):307-12.

PMID:
3501866
28.

Regional vasodilator actions of calcitonin gene-related peptide in conscious SHR.

Lappe RW, Todt JA, Wendt RL.

Peptides. 1987 Jul-Aug;8(4):747-9.

PMID:
3498157
29.
30.

Hypotensive response to atrial natriuretic factor in conscious renal hypertensive beagles.

Lee KC, Rodzinski JA, Bex FJ, Lappe RW, Wendt RL.

Clin Exp Pharmacol Physiol. 1987 Feb;14(2):137-40.

PMID:
2886239
31.
32.

Hemodynamic effects of infusion versus bolus administration of atrial natriuretic factor.

Lappe RW, Todt JA, Wendt RL.

Hypertension. 1986 Oct;8(10):866-73.

PMID:
2944826
33.

Rat atriopeptin III alters hypothalamic neuronal activity.

Haskins JT, Zingaro GJ, Lappe RW.

Neurosci Lett. 1986 Jun 30;67(3):279-84.

PMID:
2942803
34.

Effects of atrial natriuretic factor on drinking responses to central angiotensin II.

Lappe RW, Dinish JL, Bex F, Michalak K, Wendt RL.

Pharmacol Biochem Behav. 1986 Jun;24(6):1573-6.

PMID:
2942948
35.

Hemodynamic, neural, and humoral mechanisms of aortic coarctation hypertension in the rat.

Lappe RW, Brody MJ.

J Cardiovasc Pharmacol. 1986 May-Jun;8(3):656-62.

PMID:
2425187
36.

Lack of renal vasodilation during intrarenal infusion of synthetic atriopeptin II in conscious intact SHR.

Smits JF, van Essen H, Struyker-Boudier HA, Lappe RW.

Life Sci. 1986 Jan 6;38(1):81-7.

PMID:
2934600
37.

Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats.

Lappe RW, Todt JA, Wendt RL.

J Pharmacol Exp Ther. 1986 Jan;236(1):187-91.

PMID:
2867214
38.

Graded regional vasodilation with converting enzyme inhibitors in conscious spontaneously hypertensive rats.

Lappe RW, Todt JA, Wendt RL.

J Pharmacol Exp Ther. 1985 Dec;235(3):651-6.

PMID:
3001271
39.

Mechanism of action of vasoconstrictor responses to atriopeptin II in conscious SHR.

Lappe RW, Todt JA, Wendt RL.

Am J Physiol. 1985 Dec;249(6 Pt 2):R781-6.

PMID:
2933964
40.

Pharmacological evidence for rapid destruction of efferent renal nerves in rats by intrarenal infusion of 6-hydroxydopamine.

le Noble JL, Janssen BJ, Lappe RW, Brody MJ, Struyker-Boudier HA, Smits JF.

J Hypertens Suppl. 1985 Dec;3(3):S137-40.

PMID:
2856692
41.

Selective destruction of renal afferent versus efferent nerves in rats.

Lappe RW, Webb RL, Brody MJ.

Am J Physiol. 1985 Nov;249(5 Pt 2):R634-7.

PMID:
4061683
42.

Selective efferent chemical sympathectomy of rat kidneys.

LeNoble LM, Lappe RW, Brody MJ, Struyker Boudier HA, Smits JF.

Am J Physiol. 1985 Oct;249(4 Pt 2):R496-501.

PMID:
3931485
43.

Failure of atriopeptin II to cause arterial vasodilation in the conscious rat.

Lappe RW, Smits JF, Todt JA, Debets JJ, Wendt RL.

Circ Res. 1985 Apr;56(4):606-12.

PMID:
3156690
44.

Selective antagonism of humoral versus neural vasoconstrictor responses by nisoldipine.

Lappe RW, Barron KW, Faber JE, Brody MJ.

Hypertension. 1985 Mar-Apr;7(2):216-22.

PMID:
3980068
45.

Mechanisms of the central pressor action of angiotensin II in conscious rats.

Lappe RW, Brody MJ.

Am J Physiol. 1984 Jan;246(1 Pt 2):R56-62.

PMID:
6696102
46.

Effects of nifedipine on the hypotensive actions of alpha 2-agonists in conscious spontaneously hypertensive rats.

Lappe RW, Saslow BA, Wendt RL.

J Cardiovasc Pharmacol. 1984;6 Suppl 5:S748-52.

PMID:
6084118
47.

Contribution of renal sympathetic nerves to the urinary excretion of norepinephrine.

Lappe RW, Henry DP, Willis LR.

Can J Physiol Pharmacol. 1982 Aug;60(8):1067-72.

PMID:
7127218
48.

Urinary excretion of radiolabelled norepinephrine after release from renal sympathetic nerves.

Willis LR, Lappe RW, Henry DP, Evan AP, Terzian AR.

Life Sci. 1980 Dec 22-29;27(25-26):2541-6. No abstract available.

PMID:
7012510
49.

Mechanism of renal tubular secretion of norepinephrine in the rabbit.

Lappe RW, Henry DP, Willis LR.

J Pharmacol Exp Ther. 1980 Nov;215(2):443-9.

PMID:
7441508

Supplemental Content

Loading ...
Support Center